* cautious investment opportunity - low market capital *
4-years of price action resistance, a 99.96% correction, and now a higher low in price action following the oversold condition (orange column). So many reasons to be bullish on this stock. Let’s go through them.
1) As mentioned above, price action has broken out from 4 years of resistance. Following that...
There's a lot of selling pressure/resistance here at this 2.31 - 2.33 price. Once this is all bought, I am expecting a significant move to the upside. I am long the stock and the April 16 $2.50 calls. Good luck to all, and I welcome all constructive comments. I will up-date this tomorrow.
Using lines to trace price movement from MAY '19 you can draw the lines to a point at its current price where its sitting on a plateau that has proven to be a strong support through-out the assets time-span. There is potential for it to carry on at this plateau for another 24 hours or so but due to a MACD cross-over i have implemented, the likelihood of HEPA to...
Using the golden ratio as a price target, and previous magnitudes, HEPA looks primed for a run up to the $8.95-$9.93 range by EOY. The top line of the broadening formation will likely cause resistance and a chance for a nice pullback opportunity. The volume of this stock has dried up as the short volume has. Positive data has caused massive dorking of the stock...
Retested the resistance area as I said last Friday. Tough area to get through. I do expect it to go through at some point. Hopefully sooner rather than later!
Called the bottom of the chart back on April 15th. White lines are my near-term price targets for $HEPA. Still think it'll reach $2.52 for a swing trade of 70% gains!
Called bottom at 1.58 before a reversal. Chat has shown positive signs. THE first PT is 1.95. I do believe this chart will be a monster and reach 4.24 over the next few months. If you're in this play take profit as you go.
First of all, I am not an expert when it comes to pharmaceutical companies!
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently...
